SEOUL, March 21 (Reuters) - South Korea has reached a deal to buy 10 million doses of the country´s first experimental coronavirus vaccine, developed by SK Bioscience Co Ltd (302440.KS), authorities said on Monday.

The South Korean company has since August conducted Phase 3 trials of its vaccine candidate, codenamed "GBP510", jointly developed with the University of Washington´s Institute for Protein Design and aided by global drugmaker GlaxoSmithKline (GSK).